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Background: Myelodysplastic syndromes (MDS) comprise a group of malignant clonal hema-
tologic disorders characterized by ineffective hematopoiesis and propensity for progression
to  acute myeloid leukemia. Acquired mutations in the gene encoding RNA splicing factor
3B  subunit 1 (SF3B1) are highly associated with the MDS subtypes presenting ring siderob-
lasts, and represent a speciﬁc nosological entity. The effects of these mutations on clinical
outcomes are diverse and contrasting.
Methods: A cohort of 91 Brazilian MDS patients, including patients with ring sideroblasts in
the  bone marrow, were screened for mutations in the SF3B1 hotspots (exons 12–15) by direct
Sanger sequencing.
Results: SF3B1 heterozygous mutations were identiﬁed in six patients (7%), all of them
with  ring sideroblasts, thus conﬁrming the association between SF3B1 mutations and
myelodysplastic syndrome subtypes bearing this morphologic feature (frequency of 6/13,
p-value < 0.0001).
Conclusion: This is the ﬁrst screening of SF3B1 mutations in a cohort of Brazilian myelodys-
plastic syndrome patients. Our ﬁndings conﬁrm that mutations in this splicing gene
correlate with bone marrow ringed sideroblasts.© 2016 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Publishedby  Elsevier Editora Lt
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yelodysplastic syndromes (MDS) are deﬁned as clonal
ematopoietic stem cell disorders characterized by cytopenia,
yelodysplasia, ineffective hematopoiesis, and propensity for
rogression to acute myeloid leukemia.1–4 The MDS  diagno-
is is arrived at after exclusion of other myeloid neoplasms
uch as acute myeloid leukemia (AML), chronic myelomono-
ytic leukemia (CML), and myelodysplastic/myeloproliferative
eoplasms. Morphologic criteria for diagnosis include dyspla-
ia present in at least 10% of cells of any myeloid lineage
ith one or more  affected lineages of the bone marrow.5 The
ysplastic changes observed in the myeloid lineages probably
rise from a genetically transformed, primitive hematopoietic
tem cell, followed by other genetic and epigenetic changes, as
ell as stromal and immune responses in the host, that con-
ribute to phenotypic diversity, hematopoietic efﬁciency, and
usceptibility to leukemic transformation.6 MDS is categorized
n six subtypes, according to the World Health Organiza-
ion (WHO) criteria revised in 20087: refractory cytopenia
ith unilineage dysplasia (including refractory anemia, neu-
ropenia, and thrombocytopenia), refractory cytopenia with
ultilineage dysplasia, refractory anemia with excess of
lasts, MDS  with isolated del(5q), unclassiﬁable MDS,  and
efractory anemia with ring sideroblasts (RS). In the lat-
er, RS (perinuclear ring of granules formed by iron-loaded
itochondria) are observed in ≥15% of bone marrow ery-
hroid precursors. Large numbers of RS are observed in the
one marrow of more  than a quarter of patients with MDS,8
ighlighting the importance of this subgroup in the dis-
ase.
The incidence of MDS  increases at age 70 years and older9
nd the direct correlation with age suggests genetic damage
aused by hazardous exposure, e.g. chemotherapy, ionizing
adiation, diesel fuel, and smoking.2,5 A wide diversity of
utations in individual genes has been described, suggesting
hat several molecular mechanisms are involved in disease
evelopment.10 Whole-exome sequencing studies identiﬁed
ecurrent somatic mutations in spliceosome complex genes in
 signiﬁcant proportion of adult MDS  patients, with empha-
is on the SF3B1 (splicing factor 3b, subunit 1) gene, mutated
n about 20% of patients.3,11–13 High frequencies were espe-
ially observed in patients whose disease is characterized by
he presence of RS, in which SF3B1 mutations were detected
n 65%,11 75%,3 and 56%10 of patients.
The SF3B1 gene encodes the subunit 1 of the splicing fac-
or 3b protein complex, which forms the U2 small nuclear
ibonucleoprotein complex (U2 snRNP) along with splicing
actor 3a and a 12S RNA unit. This complex plays a criti-
al role in the splicing machinery and regulates the diversity
f splice variants.14 SF3B1 is also involved in the alternative
plicing program of genes that control cell cycle progression
nd apoptosis, which may elucidate the critical contribution
f mutant SF3B1 in modulating proliferation and survival of
umor cells.15 The SF3B1 protein is ubiquitously and highly
xpressed in hematopoietic lineages.16 The carboxy-terminal
wo-thirds of the subunit 1 has 22 non-identical, tandem HEAT
omain (HD) repeats, and the majority of mutations in MDS
re clustered in the region encoding the imperfect HD 4–9,16 1 6;3  8(4):320–324 321
encompassing exons 12–15 (codons 513–741). Mutations are
usually somatic de novo, and often corresponding to missense
nucleotide changes clustered mainly in three hotspots: codons
662, 666, and 700.15
In this study, 91 Brazilian MDS patients were screened for
mutations in the SF3B1 hotspots to observe the heterogeneity,
and the incidence in a Brazilian population.
Methods
Samples,  DNA  extraction,  and  polymerase  chain  reactions
Patients seen at two tertiary hematology centers in university
hospitals located in two separate regions in the country were
evaluated: one in the southeast (Ribeirão Preto, São Paulo) and
the other in northeast of Brazil (Fortaleza, Ceará) that are more
than 2600 km apart. The populations in the regions where the
two centers are located are socially, economically, and ethni-
cally diverse. Blood samples were collected from 91 patients
with MDS diagnosed and classiﬁed according to the WHO  cri-
teria (2008).7 Forty-ﬁve MDS patients seen between 2009 and
2011 at the hematology clinic, Hospital das Clínicas de Ribeirão
Preto, Universidade de São Paulo, and from whom DNA sam-
ples were previously collected and available for testing were
included in the study after MDS diagnosis was conﬁrmed.
Forty-six consecutive MDS patients seen at the hematology
clinic, Universidade Federal do Ceará, diagnosed between 2008
and 2010 were also enrolled. Samples were collected and
stored after patients had given their informed written con-
sent and the study had been approved by the Local Ethics
Committee (CEP-HCRP n. 7147/2005). The study was conducted
in accordance with the Helsinki Declaration, as revised in
2008.
Total genomic DNA was extracted from blood leukocytes
using TRIzol reagent (Ambion, Foster City, USA). All DNA
samples were ampliﬁed by polymerase chain reaction (PCR)
using speciﬁc primers for exons 12–15 of the SF3B1 gene
(RefSeq NM 012433.2) and Platinum Taq DNA Polymerase kit
(Invitrogen, Carlsbad, USA) according to the manufacturer’s
instructions. Primer sequences used in ampliﬁcation reac-
tions were designed according to Malcovati et al.17 The quality
of PCR products was assessed by denaturing 1.5% agarose gel
electrophoresis under standard conditions. The PCR products
were puriﬁed using the QIAquick PCR Puriﬁcation kit (Qiagen,
Hilden, Germany) according to the manufacturer’s recommen-
dations.
Sanger  sequencing  and  analysis
Puriﬁed PCR fragments were directly sequenced in both
directions. Sequencing reactions were performed using the
DYEnamic ET Dye Terminator Cycle Sequencing kit and
the MegaBACE Long Read Matrix equipment (GE Health-
care Life Sciences, Uppsala, Sweden). Chromatograms were
analyzed through the CLC Main Workbench software v5.7
18used to predict the impact of the detected amino acid sub-
stitutions on the structure and function of SF3B1 human
protein.
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Exon 14 – E622DA
B
G>T A>G
Score of possibly damaging
0.930.87
0.00 0.20 0.40 0.60 0.80 1.00 0.00
ACTGGTATTAAGATTGTACAAC
ACTGGTATTAGGATTGTACAAC
ACTGGTATTAAGATTGTACAAC
ATGAGCAGCAGNAAGT-CGGAC
ATGAGCAGCAGGAAGTTCGGAC
ATGAGCAGCAGGAAGTTCGGAC
ACATGGATGAGTATGTCCGTA
ACATGGATGATTATGTCCGTA
ACATGGATGAGTATGTCCGTA
 0.20 0.40 0.60 0.80 1.00 0.00 0.20 0.40 0.60 0.80 1.00
0.99
G>A
Exon 14 – K666R Exon 15 – K700E
Figure 1 – Heterozygous mutations in SF3B1 found in six MDS  patients. (A) Chromatograms of regions of exons 14 and 15
presenting nucleotide substitutions that lead to amino acid changes in the SF3B1 protein; one patient exhibited an E622D
substitution, another one, a K666R, and four patients presented the most common described substitution, K700E. (B)
Representation of the impact of each amino acid substitution on the protein structure and function, as well as a predicted
robascore ranging from 0 to 1, in which 1 represents the higher p
Statistical  analysis
Statistical analysis was performed in the R software environ-
ment (http://www.r-project.org/). Pairwise comparisons were
performed by Mann–Whitney test, and by two-sided Fisher
exact test (CI = 0.95) for quantitative and categorical variables,
respectively.
Results
Sanger sequencing was performed in 91 Brazilian MDS
patients and three non-synonymous SF3B1 heterozygous
mutations were identiﬁed, leading to missense substitutions
in six unrelated patients. The most common recurrent SF3B1
mutation affected codon 700 (K700E, four out of six patients);
one patient harbored a mutation in codon 622 (E622D), and
another one, in codon 666 (K666R) (Figure 1A). The predic-
tion of mutation malignancy or mildness showed mutations
as probably damaging for the protein structure and function,
with high scores, ranging from 0.87 to 0.99 (Figure 1B). Con-
sidering WHO  subtypes, differences were detected comparing
wild type and mutated groups (p-value = 0.003; Table 1). A
strong association between SF3B1 mutation and disease phe-
notype with RS (p-value < 0.0001) was observed in this cohort.
Thirteen patients (14.2%) were found with RS and all six SF3B1
mutated patients (6/13) presented at least 15% of RS in the
bone marrow. The correlation of SF3B1 mutations in MDS with
RS, the median age, gender, karyotype risk comparisons, and
clinical characteristics of patients are shown in Table 1.
DiscussionThis study found that in a Brazilian cohort of MDS patients,
SF3B1 is mutated in about 7% of patients, all of whom have
RS in the bone marrow. The current diagnostic criteria (WHO,bility of damaged protein.
2008) for MDS  are mainly based on morphology4 but Malcovati
et al.19 demonstrated the feasibility of including a molecular
classiﬁcation in myeloid neoplasms. The inclusion of molec-
ular analysis might be valuable not just for diagnosis, but also
for prognostic purposes and evaluation of disease progres-
sion. Therefore, the importance of the mutational analysis
improves clinical decision making, as different point muta-
tions in MDS have distinct effects on disease phenotype and
prognosis.19,20 Apart from the WHO  category, SF3B1 mutation
status has a positive predictive value (97.7%) for disease phe-
notype with RS, whereas the absence of RS had a negative
predictive value (97.8%) for the mutations.4,17
How SF3B1 mutations contribute to MDS  pathogenesis is
still unclear. The potential mechanism responsible for iron
accumulation in the mitochondria of erythroblasts in MDS
characterized by RS is the reduced expression of the ABCB7
gene, which plays essential roles in both mitochondrial iron
homeostasis and hematopoiesis.21,22 The down-regulation of
ABCB7 has previously been associated with over-expression
of FTMT (encoding mitochondrial ferritin) in hematopoietic
progenitors.23,24 The mitochondrial ferritin has ferroxidase
activity, capturing iron in the ferrous form, depositing as ferric
hydroxides after oxidation. The accumulation of this protein
in erythroblasts was accompanied by markedly reduced ery-
throid growth in vitro due to the down-regulation of ABCB7.25
The abnormal mRNA  splicing due to mutated SF3B1 might
lead to an abnormal ABCB7 protein, deregulating mitochon-
drial ferritin in the immature red blood cells, thus culminating
in the disease phenotype.
Conversely, Visconte et al.26 did not observe any differences
in gene expression or exon usage in genes of the mitochondrial
pathway, such as ABCB7 and FTMT,  in SF3B1-mutant refractory
anemia with ring sideroblasts patients. These ﬁnds suggest
that different biological pathways are involved in the accumu-
lation of iron in hereditary and acquired sideroblastic anemia.
Although the authors did not ﬁnd differences in expression
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Table 1 – Clinical characteristics of 91 MDS  patients according to SF3B1 mutation status.
Characteristic All
Patients
(n = 91)
SF3B1
Wild  type
(n = 85)
SF3B1
Mutated
(n  = 6)
p-value
Age (years) 0.14
Median 69 67 77
Range 15–91 15–91 28–83
Gender 0.39
Female (n) 53 48 5
WHO subtype 0.003
RA no. 3  3 0
RARS (n) 7  3 4
RAEB-I (n) 3 3 0
RAEB-II (n) 6 6 0
RCMD (n) 52 52 1
MDS del (5q) (n) 3 3 0
RCUD (n) 10 10 0
Secondary MDS (n) 6 5 1
Non-classiﬁed (n) 1 1 0
Ring sideroblasts <0.0001
Present (n) 13 7 6
Not classiﬁed (n) 6 6 0
Karyotype riska 0.34
Low (n) 19 16 3
Intermediate 1 (n) 46  44 2
Intermediate 2 (n) 6  6 0
High (n) 2 2 0
Not classiﬁed (n) 18 17 1
RA: refractory anemia; RARS: refractory anemia with ring sideroblasts; RAEB-I, II: refractory anemia with excess blasts; RCMD: refractory
cytopenia with multilineage dysplasia; MDS del (5q): MDS with isolated 5q deletion; RCUD: refractory cytopenia with unilineage dysplasia.
a Based on the International Prognostic Scoring System.
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ievels of genes relevant to the MDS  pathophysiology (such as
SXL1, CBL, EZH1, and RUNX3), these genes were found alter-
atively spliced in at least one exon, suggesting that SF3B1
utations are founder mutations that promote subsequent
cquisition of genetic abnormalities.
SF3B1 mutations might lead to proteins exhibiting gain- or
oss-of-function, which may foster, for instance, clonal expan-
ion and dominance of hematopoietic progenitors carrying
he mutation. Malcovati et al.17 showed the assessment of
F3B1 mutant allele burden revealing the presence of a domi-
ant clone with a heterozygous mutation in most of the cases.
oreover, patients carrying this molecular lesion presented
 signiﬁcantly better overall survival compared with those
ithout the mutation, which indicates that SF3B1 mutation
nalysis is an important predictor of clinical outcomes in these
isorders.17
This study is the ﬁrst to report on SF3B1 gene mutations
n Brazilian MDS  patients. The frequency of mutations in this
plicing gene in patients presenting RS tended to be lower than
escribed in previous studies in European and North American
opulations. This apparent disagreement may reﬂect both the
eterogeneity of the Brazilian population due to miscegena-
ion and/or the restricted analysis performed in this study, as it
ocused on hotspot mutations only. MDS  is under-diagnosed
n Brazil,27 which may also contribute to the differences inmutation frequency observed in the present study. The impor-
tance of the molecular analysis in a heterogeneous group of
diseases such as MDS is undisputable, especially for improving
diagnosis and prognosis.
Conclusion
Six heterozygous mutations in the SF3B1 gene were identiﬁed
in a cohort of 91 Brazilian MDS patients, which were highly cor-
related with the presence of bone marrow RS, similar to what
was previously reported in studies of different populations.
This observation highlights the importance of molecular anal-
ysis in these diseases besides morphological and cytogenetics
analyses of the hematopoietic lineages.
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